Preventable Vaccines Market Will Reflect Significant Growth Prospects during 2013-2019

The use of preventable vaccines is to avoid the occurrence of an infectious disease, which is preventable by the use of vaccines. The occurrence of death due to a vaccine-preventable disease is termed as vaccine-preventable death, the reason being failure to attain vaccines in time, lack of access to vaccines and financial limitations. The WHO has estimated that in the year 2008, around 1.5 million deaths in the children aged less than 5 years were due to vaccine-preventable diseases. This accounted for about 17% of the global mortality of children aged less than 5 years. Further, it also stated that diphtheria, hepatitis B, pertussis, influenza, meningitis, measles, mumps, poliomyelitis, yellow fever and neonatal tetanus are some of the most frequent and serious vaccine-preventable diseases.

Read Full Report: http://www.transparencymarketresearch.com/preventable-vaccines-market.html

With the introduction of preventable vaccines, many nations are taking up immunization programs with the aim of eradicating the above mentioned indications. For instance, with extensive immunization programs small pox has been successfully eradicated globally. A technical review in the U.S. highlights other indications for eradication such as measles, mumps, hepatitis B and rubella. Progression of biomedical research, technological advances, government-supported immunization programs and increasing incidences of the vaccine-preventable diseases are some of the factors that boost the demand of the development of effective preventable vaccines. The preventable vaccines market holds immense growth potential due to its rising demand and wide application areas.

Preventable vaccines market can be segmented on the basis on type of vaccines, indications and geography. The market by vaccine type includes live attenuated vaccines, killed vaccines, genetically modified vaccines and others. The indications segment comprises of various vaccine preventable diseases such as hepatitis B, poliomyelitis, measles, neonatal tetanus, diphtheria, pertussis and others. Geographical segmentation involves the study of preventable vaccines market in four major regions namely North America, Europe, Asia-Pacific and Rest of the World (RoW).

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2027

Some of the major factors driving the growth of this market includes high demand for vaccination across the globe, rigorous research and development initiatives for the manufacturing of preventable vaccines, favorable government funding towards these vaccines and rising prevalence of vaccine preventable diseases. However, surfacing regional players and misuse of the government resources may challenge the growth of the market. The major players competing in the preventable vaccines market are Emergent Biosciences, Inc., Novartis AG, GlaxoSmithKline plc, Merck & Co, Inc., Pfizer, Inc. and Sanofi.

Growing incidence of cancer cases around the globe propels the Small Molecule Kinase Inhibitors Market

Small molecule kinase inhibitors are a form of enzyme inhibitors and are mostly used for the treatment of cancer. Protein kinase aids in the development and progression of tumors and small molecule kinase inhibitors help in obstructing unregulated cell cycle. The growing incidence of cancer cases around the globe is one of the major factors that propel the small molecule kinase inhibitors market. This has driven pharma companies and regulatory bodies to further speed up the process of clinical trials and drug approvals.

The research report analyzing the small molecule kinase inhibitors market studies the industrial landscape and presents a qualitative and quantitative portrait of the expected performance of the market from 2013 to 2019.

The data is derived from primary and secondary research, ensuring absolutely unbiased and authentic evaluation of the small molecule kinase inhibitors market. With the help of Porter’s five forces analysis, the report studies the role of buyers, suppliers, substitutes, new entrants, and competitors in the global market. Growth factors, challenges, and opportunities are identified and discussed at length and added emphasis is laid on government regulations that govern that pharmaceutical industry.

Overview of the small molecule kinase inhibitors market

The small molecule kinase inhibitors market is projected to witness robust growth in the coming years with rising popularity of the next generation of kinase inhibitor drugs, multi-targeted kinase inhibitors, and combination drug therapies. The use of kinase inhibitors for the treatment of various oncology and non-oncology diseases has grown, and while cancer end-use application areas are much stronger, non-cancer therapies are bound to gain interest.

Key kinase inhibitor drugs that have made a significant contribution to the global market include Sorafenib, Gefitinib, Iressa, Temsirolimus, Imatinib, Dasatinib, Rapamycin, Nilotinib, Everolimus, Sunitinib, Erlotinib, and Lapatinib. These commercially-available drugs are designed to target and treat specific diseases. There are numerous small molecule kinase inhibitor drugs in the pipeline, a factor that is anticipated to boost the global market. These pipeline drugs include Pazopanib, Cediranib, CP-690550, Bosutinib, Vandetanib, Alvocidib, Motesanib, and Ridaforolimus.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2110

Despite the availability of a number of kinase inhibitors, the anticipated rise in cancer cases all over the world poses high potential for the growth of the small molecule kinase inhibitors market. However, strict regulatory riders, lengthy approval procedures, and mounting costs of next-generation cancer drugs are matters of concern that hamper the expansion of the small molecule kinase inhibitors market.

Companies mentioned in the research report

Prominent names in the small molecule kinase inhibitors market include Bristol-Myers Squibb, Amgen, KAI Pharmaceuticals, Onyx Pharmaceuticals, Wyeth, OSI Pharmaceuticals, Glaxo SmithKline, Merck & Co, Pfizer, Bayer Schering Pharma, Roche, Sanofi-Aventis, AstraZeneca, Novartis, Genentech, and Celgene Corporation. The research study discusses these companies with respect to company overview, financial standing, product portfolio, recent developments in the small molecule kinase inhibitors market, mergers and acquisitions, business strategies, and SWOT analysis.

Small Molecule Targeted Cancer Therapy Market - An Overview of Growth Factors

Small molecule targeted cancer therapies are drugs designed to block the growth of cancerous cells. Conventional cytotoxic medications and chemotherapies usually destroys rapidly dividing cancer cells by inhibiting cell division process. However, small molecule targeted therapies destroys cancerous cells with fewer side effects and high precision. Small molecule targeted cancer therapies can be used for the treatment of various cancers such as prostate cancer, multiple myeloma, breast cancer, lymphoma, melanoma and other cancers.

Read Full Report: http://www.transparencymarketresearch.com/small-molecule-targeted-cancer-therapy-market.html

Targeted cancer drugs are broadly classified as follows:

• Small Molecules
• Monoclonal Antibodies
• Small Molecule Drug conjugates

Small molecules can further be classified as follows:

• Small molecule proteasome inhibitor (e.g. Bortezomib)
• Small molecule cyclin-dependent kinase inhibitor (e.g. Seliciclib)
• Small molecule tyrosine kinase inhibitor (e.g. Imatinib)

Geographically, North America is the leading market due to the rise incancer cases. According to the International Agency for Research on Cancer (IARC), around 13 million new cancer cases has been diagnosed worldwide. Moreover, according to the World Cancer Report, incidence rate of cancer could further rise by 50% to 15 million new cancer cases by 2020. Furthermore, the European and Asian-Pacific regions are expected to witness increased market traction due to commercialization of target oriented economic drugs.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2107

The major factors driving this market are rise in incidence rate of cancer, minimal adverse effects, targeted approach and high adoption rate. Additionally, more number of blockbuster drugs such as Novartis’s Glivec are losing their patents, leaving significant opportunities for manufacturers of targeted cancer drugs. However, high developmental costs, stringent regulatory policies andlow awareness are some of the restraints that could impede the growth of the market.

Some of the market players in this industry segment are Abbott Laboratories, Bayer HealthCare AG, Boehringer Ingelheim GmbH, CytokineticsInc., GlaxoSmithKline plc, Hospira Inc. , OncoGenex Pharmaceuticals Inc., and others.

Neuroprotective Products Market grows with rise in incidence and prevalence rate of neurodegenerative diseases

In a new report, titled “Neuroprotective Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019,” Transparency Market Research (TMR) provides an in-depth assessment of the various factors supporting and restraining the market’s growth. The market is primarily gaining from the increasing incidence of neurodegenerative diseases such as Amyotrophic lateral sclerosis, Parkinson’s disease, Huntington’s disease, and Alzheimer’s disease.

Read Full Report: http://www.transparencymarketresearch.com/neuroprotective-products-market.html

The report provides a comprehensive study on the prevailing trends in the global neuroprotective products market, highlighting the drivers and restraints impacting its trajectory. To help the stakeholders gain a better perspective, the report also includes refined outlook for the market’s future. In addition, Porter’s five forces is conducted to gauge the bargaining position of suppliers and buyers. The analysis also presents insights into the degree of competition prevailing in the market. Besides these, the report compiles exhaustive information aimed at helping the leading market players take crucial business decisions.

As per TMR, the rising demand for advanced medication in the treatment of brain injury will be the key factor driving the global neuroprotective products market. Despite positive growth trends, stringent approval norms and high development costs could hamper the market’s growth to an extent.

Regionally, the global neuroprotective market can be segmented in Asia Pacific, Europe, North America, and Rest of the World. Currently, North America leads as the primary market due to the increasing number of neurodegenerative disorder cases it is witnessing over the last few years. As per the findings of the Alzheimer’s Association (AA), over 5.4 million people in the U.S. were diagnosed with Alzheimer’s disease in 2012. Furthermore, as per the Parkinson’s disease Foundation, every year around 60,000 Americans are diagnosed with the condition. With very little likelihood of the incidence to reduce anytime in the near future, the demand for neuroprotective products is likely to increase.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1976

Furthermore, Asia Pacific and Europe are expected to provide considerable opportunities to the market due to the rising incidence of neurodegenerative disorders witnessed in the region. The commercialization of personal medication will also create growth opportunities for the market in the aforementioned regions.

Besides the regional segmentation, by product the global neuroprotective products market can be classified into anti-inflammatory agents, anti-excitotoxic agents, neurotropic factors, metal ion chelators, ion channel modulations, mitochondrial dysfunction regulators, apoptosis inhibitors, gene therapy, and free radical trappers. Furthermore, based on medical condition, the market can be segmented into Multiple Sclerosis, Ocular Degeneration, Amyotrophic Lateral Sclerosis, Huntington\'s Disease, Alzheimer\'s Disease, Peripheral neuropathy, Parkinson\'s Disease, Brain Injury.

The report provides a detailed assessment of the various factors influencing the market’s growth across the segmentation. In addition the report profiles some of the leading players operating in the global neuroprotective products market. These include Genervon Biopharmaceuticals LLC, BHR Pharma LLC, Neuren Pharmaceuticals Limited, NeuroVive Pharmaceutical AB, Varinel Inc., and Allon Therapeutics Inc. Using SWOT analysis, the strengths and weaknesses of the companies profiled are studied in detail. The analysis is intended to help the market players identify the threats and opportunities that they might witness in the near future.

Perennial Allergic Rhinitis Market grows with rising awareness about the disease and its diagnosis

Rhinitis is an acute disease of the nasal system. Rhinitis is the irritation and inflammation of the internal lining and mucous membrane of the nose. The rhinitis is one of the short term and environment related disorders, which is identified by common symptoms, such as, runny nose, stuffy nose and post-nasal drip.

Among various types of rhinitis, allergic rhinitis is the most common disease. Allergic rhinitis, as the name indicates, occurs due to various allergy propelling factors, such as, pollen grains, dust, mist, fog, and other airborne allergens. When these allergens are inhaled by immune-sensitive person, it triggers the production of IgE (immunoglobulin E antibody). IgE triggers the histamine secretion, which leads to irritation and inflammation of mucous membrane. Perennial allergic rhinitis is the most common and frequently occurring type of allergic rhinitis.

Read Full Report: http://www.transparencymarketresearch.com/perennial-allergic-rhinitis-market.html

The major symptoms of the disease include itching, sneezing, rhinorrhea, nasal obstruction and congestion. Sometimes, rhinitis may occur due to chronic diseases, such as, asthma, eczema and depression. The causes of the disease include pollens and airborne allergens of various natural origin, such as, trees, weeds and grasses. The disease is diagnosed by using Radio Allergo Sorbent Testing (RAST) blood test, skin test (patch test), skin prick test, and allergen sensitivity test.

The market of perennial allergic rhinitis is segmented on the basis of drugs classes used for the treatment, such as, steroids, antihistamines, allergen immunotherapy formulations, decongestants, and other complimentary treatments. Steroids class mainly includes intranasal corticosteroids, prednisolone, beclometasone, and triamcinolone acetonide. Whereas, antihistamines class include citrizine, chlorphenamine, promethazine, acrivastine, loratadine and others. Allergen immunotherapy formulations mainly include desensitizing vaccines. Decongestants mainly include phenylephrine hydrochloride and others. Other treatments include cromolyn formulations (sodium cromoglycate as anti-inflammatory agent), leukotriene receptor antagonists and others. Further, the market is segmented on the basis of geography, such as North America, Europe, Asia-Pacific and Rest of the World (RoW). The European region is the most dominating market in the world, owing to large number of perennial allergic rhinitis diagnosed patients. On the other hand, Asia-Pacific and RoW regions are the most promising markets in upcoming period, owing to rising awareness and treatment of disease and rising prevalence of disorder, and growth of medical infrastructure.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2936

The market of perennial allergic rhinitis is expected to show steady growth during the forecast period 2014 – 2020. This growth is driven by various factors, such as extensive R&D practices to develop new and more effective products and formulations, rising number of patients, changes in lifestyle and other environmental conditions. These factors are coupled with rising awareness about the disease and its diagnosis. According to World Allergy Organization (WAO), the prevalence of allergic rhinitis varies from 1.4% to 40% in various countries of the world. European and APAC countries are the most prevalent to disease, due to frequently varying environmental and climatic conditions. According to American College of Asthma, Allergy and Immunology (ACAAI), in 2010, around 16.9 million adults and 6.7 million children were diagnosed with hay fever. This high prevalence of the disease is anticipated to propel the growth of the market during the forecast period 2014 – 2020. Further, due to extensive R&D practices, a number of new formulations for the treatment of perennial allergic rhinitis are under pipeline studies. For instance, formulations like S-555739, desloratadine, GMNL-32 and many others are under pipeline studies and are expected to enter in the market during upcoming 5-10 years.

Hence, this fact is expected to fuel growth of the market. Major restraints include ignorance towards the disease and side effects of the therapy, which may limit the growth of the market to certain extent.

Some of the major players operating in this market include Pfizer, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Hanmi Pharmaceuticals, Inc. amongst others.

Critical Limb Ischemia Treatment Market driven by rising incidence of CLI

Critical limb ischemia (CLI) is a kind of peripheral arterial disease (PAD) in which chronic inflammation associated with atherosclerosis (progressive thickening of arteries lining) causes reduced blood flow to the extremities (legs, feet and hands), leading to severe pain and ulcers or sore. Some major risk factors for critical limb ischemia comprise aging (people aged 60 or over are at high risk of developing this diseased condition), diabetes, obesity, high cholesterol level, sedentary lifestyle, smoking and high blood pressure. Critical limb ischemia is associated with most common symptoms such as severe pain and numbness in the legs and feet when a person is in sedentary stage (rest pain), ulcers or skin sores and tissue necrosis (gangrene).

Read Full Report: http://www.transparencymarketresearch.com/critical-limb-ischemia-treatment.html

Critical limb ischemia being severe condition of PAD does not improve on its own and requires comprehensive treatment by a vascular surgeon. Treatment focuses on reducing the number of risk factors, relieving pain, reduction of blood pressure and cholesterol level, and to preserve the limb. However, there is no specific drug approved by the United States Food and Drug Administration (FDA) for treating CLI. There are many companies including Aastrom Biosciences, Biotronik AG, United Therapeutics and Sanofi that are striving to develop drug meant to cure CLI and PAD. Endovascular therapy is one of the common options in the care of CLI. Angioplasty, stents, laser atherectomy and directional atherectomy are some major endovascular procedures that are used to treat critical limb ischemia. Treatment may also involve surgical procedure for removing arterial blockage.

Worldwide increasing geriatric population, rising incidence of CLI and participation of a large number of companies to develop drugs supposed to treat CLI are among the major factors driving the market growth across the globe. Statistics released by the United Nations (UN) suggest that the global share of elderly population (aged 60 years and over) as a proportion of the global population has been increased from 9.2% in 1990 to 11.7% in 2013, and is expected to reach 21.1% by the end of 2050. In 2013, nearly 841 million people were aged 60 years and over which is likely to reach more than 2 billion by 2050.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2770

As people age they are at high risk of developing CLI, therefore, increasing elderly population is expected to drive the market growth during the forecast period. According to Vascular Disease Management, the prevalence of CLI has been estimated to be 300 per million inhabitants. In the United States, approximately 1 million people are affected with CLI. However, an analysis suggested by the Sage Group indicates that nearly 2 million people in the U.S. are living with CLI and owing to continuous rise in geriatric population the prevalence is expected to reach 3.5 million by 2020. Such high prevalence of people with CLI represents a favorable market for critical limb ischemia treatment market. In terms of geography, North America, Europe, Asia-Pacific and Rest of the World (RoW) are the four major markets for critical limb ischemia. Of these North America represents the largest market, followed by Europe, Asia-Pacific and Rest of the World (RoW).

Some of the major companies and research institution that are actively participating to develop medicines for treating critical limb ischemia include Aastrom Biosciences, Mahidol University, University Hospital Ostrava, MultiGene Vascular Systems Ltd. University of Southern California, Harvest Technologies, Seoul Veterans Hospital, GWT-TUD GmbH, Biotronik AG, United Therapeutics, Sanofi, Asklepios Kliniken Hamburg GmbH, Anesiva, Inc. and medac GmbH.

Blood Glucose Test Strips Market: New Business Opportunities & Investment Research Report 2019

Blood glucose or blood sugar refers to the sugar passed through the blood stream that is responsible for ensuring the energy supply to all the cells in the body. The regulation of blood glucose levels is essential in order to maintain the normal levels thereby maintaining hemostasis (maintaining a stable or equilibrium condition in the blood’s internal environment). The state of hemostasis is necessary for our bodies to ensure proper functionality.

There exist different types of blood glucose measurement tests performed such as fasting blood sugar test, postprandial blood sugar, oral glucose tolerance test, glycohemoglobin A1c testing and random blood sugar testing. Deviation in blood glucose levels from the normal range results in the development of disorders such as hyperglycemia and hypoglycemia. Hyperglycemia refers to a condition characterized by high levels of blood sugar than normal range whereas hypoglycemia refers to a condition characterized by lower blood glucose levels than normal range. Research studies have proved that higher levels of blood glucose levels lead to increased risk of developing cardiovascular diseases both in diabetic and non-diabetic population.

Read Full Report: http://www.transparencymarketresearch.com/blood-glucose-test-strips.html

Blood glucose monitoring is referred to the regular testing of glycemia (testing the levels of glucose). Usually the blood glucose levels are monitored by either using a glucose meter comprising lancets, test strips and logbooks. In January 2014, the U.S. Food and Drug Administration (FDA) proposed the new draft guidance for blood glucose test strips. The FDA has issued for the first time two separate guidance drafts for blood glucose test strips of which one is focused on point of care prescription meters (used in hospitals) and the other for over-the-counter (OTC) products.

The scope for allowable range of errors has been tightened from plus or minus 20% to plus or minus 15%. Similarly, the range of errors in case of point of care meters is also tightened. The other requirements would be the disinfection requirements and the packaged maters would contain the information about the accuracy results of the products. This would help the buyers to select the appropriate test strips. Another major requirement that FDA had added is that it would review the manufacturers test strips release lot that means there would be more stringent scrutiny for the clearance of test strips. Hence, these guidelines would ensure safety along with high reliability and accuracy and also reduce the probability of product recalls by the respective companies.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2424

The market for blood glucose test strips can be segmented based on the test strips available for hospital use and over the counter products. Also, a detailed geographical landscape elucidating the market trends for four major geographies can be provided. The major factors favoring the growth of the blood glucose test strips market is consistent increase in the prevalence of diabetes along with increasing obesity and increased physical inactivity. As per the data enumerated by the International Diabetes Federation, in the year 2013 there are around 382 million people suffering from diabetes worldwide of which 37 million are Americans, 72 million people in South East Asian countries and around 56 million in European countries and others. In addition, rise in technological advances and increased awareness about diabetes is leading to increased diagnosis rates both at hospitals and at individual level.

These factors would in turn enhance the adoption of blood glucose test strips and drive the market growth. On the other hand, lack of accuracy, reliability, and increasing product recalls by several manufacturers would impede the market growth. Some of the key market players competing in this market are Abbott Laboratories, Bayer Healthcare AG, LifeScan, Inc., and F.Hoffmann-La Roche Ltd.

Life Sciences Tools Market witness handsome growth in upcoming years

Life science is the field of science that deals with the study of variety of living organisms, such as, plants, animals, human beings and microorganisms. Life sciences is also considered as a multidisciplinary scientific and research field as it comprises of a wide number of fields of study, such as molecular biology, genetics, biotechnology, cell biology, biochemistry, biomedicine etc. Some of the major life sciences tools include, instruments, reagents, consumables and services that are offered to various academic, medical, scientific and research professionals worldwide.

Life sciences tools market can be classified into five major segments, namely, genomics, proteomics, cell biology, other analytical tools and laboratory supplies & disposables. The genomics tools segment can be further classified into sub segments, such as, PCR, digital PCR, qPCR, CE sequencing, microarrays, next generation/third generation sequencing and molecular biology. The proteomics tools can be further segmented into segments such as, ELISA, protein isolation and analysis, protein microarrays, protein production and western blotting tools. And, the other analytical tools will include, media and sera, basic cell biology reagents, flow cytometry, electroporation, transfection, microscopy, cell culture equipment, whole cell imaging, cells and tissues. The laboratory supplies and disposables include sub segments such as, mass spectroscopy, liquid chromatography, multiplex technologies, in vivo study, sample preparation, glassware, LIMS and magnetic beads.

Some of the major driving factors for the growth of life sciences tools market include, rising demand from various research and pharmaceutical companies, increasing incidences of new and drug resistant diseases and technological advancement in various fields of life sciences. Various research and pharmaceutical companies increasingly demand for better and improved reagents and other instruments that will add to their faster research and drug development processes. Also, various life science tools do not face strict regulations for their approval and marketing such as other drugs and other medical devices. Increasing incidences of infectious diseases and related research and development of new treatment methods require assistance of various life science tools, which will further help in the growth of this market. Current ongoing innovations and technological advancements in life science instruments will add to the growth of life sciences tools market in the near future.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2358

Geographically, North America dominates the life sciences tools market followed by Europe. Major factors responsible for the growth of this market in these regions were high rate of research and drug development activities in the region and most of the research and big pharmaceutical firms are located in these regions. However, Asia-Pacific represents the most lucrative market for the life sciences tools due to its rapid rate of growth in recent past. The major factors responsible for this region’s fast rate of growth include increasing demand for various life sciences tools due to rising healthcare expenditure in the region along with the rising economic condition of various countries of the region.

Some of the major players operating in the life sciences tools market are Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., EMD Millipore (Merck KGaA), Life Technologies (Thermo Fisher Scientific Corporation), F. Hoffmann-La Roche Ltd. and Sigma-Aldrich Corporation.

Life Science and Chemical Instrumentation Market: Reporting and evaluation of recent industry developments

Global Life Science and Chemical Instrumentation Market: Overview

With investments in clinical research progressively rising, spending on instrumentation used for analytical chemistry is expected to rise continually as well. Analytical chemistry has proven useful in studying the composition of materials to find new applications for them or to modify their composition as desired. This end cannot possibly be met without the use of proper life science and chemical instrumentation. The global market for life sciences and chemical instrumentation is thus looking at a promising future ahead. TMR projects a positive outlook for the global life science and chemical instrumentation market through the forecast period. The market is expected to register a high single-digit CAGR.

From determining how safe a food sample is to analyzing DNA to discovering new drugs for chronic diseases, the use of life science and chemical instrumentation are myriad. The market is thus expected to fare well thanks to its many end users and application areas. This aspect will keep growth a constant in the life science and chemical instrumentation market.

The report on the global life science and chemical instrumentation market evaluates and prioritizes the factors that will influence its growth over the report’s forecast period. By meticulously segmenting the market on the basis of type of technology, end use, application, and geography, TMR’s analysts are able to dive deep into the present dynamics of the market and emerge with data that can aid prudent decisions. A holistic overview of the prevailing competitive environment in the market makes this report a valuable tool for tracking the strategies that competitors are expected to adopt.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11933

Global Life Science and Chemical Instrumentation Market: Drivers and Restraints

With governments across the world setting up incubation programs and special economic zones for companies in fields such as biotechnology and pure chemistry, the demand for life sciences and chemical instrumentation is expected to continually rise. Moreover, regulatory authorities in emerging countries such as Brazil, India, China, and Russia are now watching the F&B and pharma industries more closely in the wake of food scandals and pharmaceutical product recalls. This will compel companies to adhere to the highest quality standards, which will indirectly lead to higher sales of life science and chemical instrumentation products.

The cost of developing and marketing such instruments, however, can be a stumbling block for many market players. With companies naturally passing on costs to the consumers, the latter may be prompted to find more affordable alternatives, thwarting the growth plans of market players.

Global Life Science and Chemical Instrumentation Market: Segmentation

The most common uses of life science and chemical instrumentation market are seen in healthcare research agencies, contract research organizations, pharmaceutical and biotech entities, clinical and diagnostic laboratories, and academic research institutions. It is primarily the diagnosis technologies in question that determine the nature of chemical and life science instrumentation to be used.

Based on the area of usage, the life science and chemical instrumentation market can be segmented thus: Electrophoresis, chromatography, laboratory automation, DNA sequencers and amplifiers, flow cytometry, spectrometry, and microarrays. The demand for DNA amplifiers and sequencers is expected to show an upswing on the back of rising investments in biotechnology, which have dramatically risen in the post-recession phase.

The outlook for the chromatography segment, too, is positive. This can be ascribed to the growing uses of chromatography-coupled with a remarkable spike in UHPLC chromatography-across diverse verticals. Companies such as Agilent, Shimadzu, and Waters Corporation are at the forefront of innovation, enabling them to capture a larger section of the market in this space. The report also expects a healthy upswing in the demand for instruments such as fume hoods, laboratory balances, and centrifuges.

Request For Custom Research: http://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=11933

The applications of life science and chemical instrumentation devices include, but are not limited to: Forensic technologies, biotechnology, environment, agriculture, chemicals, food and beverage, and pharmaceuticals. The biotech and pharmaceutical sectors will be the growth engine for life science and chemical instrumentation market by application. Intensive research programs in developed nations will indirectly fuel sales of life science and chemical instrumentation. The trend is only just beginning to take shape in developing nations, and could soon be a high-impact driver.

By geography, the global life science and chemical instrumentation market has been divided into: North America, Asia Pacific, Europe, MENA, and Rest of the World.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Next Generation Sequencers Market: Huge opportunity for NGS technology in the field of biological drug discovery

Next generation sequencers are used inthe sequencing technologies which massively parallelize the DNA sequencing process rather than being limited to single or few fragments of DNA. The next generation sequencing (NGS) technology enables rapid sequencing and produce thousands and millions of sequences in single run with the use of next generation sequencers. Such technologies have been rapidly developing owing to continuous demand for high-throughput (next generation) sequencers which tend to lower the cost of DNA sequencing.

The global next generation sequencers market is categorized on the basis of technologies segmented as single-molecule real-time sequencing (SMRT), ion semiconductor sequencing, pyrosequencing, sequencing by synthesis, sequencing by ligation and chain termination. All these technologies are proprietary and protected through intellectual property rights. The NGS technologies have overcome the limitations of capillary electrophoresis -based Sanger Sequencing with respect to throughput, scalability, speed and resolution and therefore highly preferred these days.

Geographically, the global market for next generation sequencers is segmented into four major regions, namely, North America, Europe, Asia-Pacific and rest of the world. The funding from federal government and agencies in the U.S. and Canada makes the North American region, the largest market for next generation sequencers. The European and Asian market are also expected to grow substantially due to encouragement by government to use NGS technology.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=574

The major driving factorsfor the global next generation sequencers market are the low cost and speed for DNA sequencing. Other market drivers include the rapid adoption of technology by researchers and academicians, utility for varied application in sequencing and its usability as a substitute for microarray technology.Reduction in the research expenditures by government and university are temporarily impeding the market growth, however the scenario is expected to change once the global economy revives. There is a huge opportunity for NGS technology in the field of biological drug discovery, personalized medicine, agricultural & animal research.

Some of the market players in this industry segment are Agilent Technologies, Inc.,Illumina, Inc., BGI (Beijing Genomics Institute), Biomatters, Ltd., Pacific Biosciences, Dnastar, Inc., Oxford Nanorpore Technologies, Ltd., EMC Corporation, Life Technologies Corporation, Genomatix Software GMBH, Partek Incorporated, Macrogen, Inc., OcimumBiosolutions, Ltd., Perkinelmer, Inc., Qiagen N.V., GATC biotech AG and Knome, Inc.

Malaria Diagnostics Market: An insight on the important factors and trends influencing the market

Malaria is caused by the Plasmodium parasite, which is transmitted by the female Anopheles mosquito. As per the WHO, there were around 203 mn cases of malaria worldwide in 2012, resulting in approximately 627,000 deaths. The diagnosis of malaria involves detection with the help of blood tests and microscopy. Early and accurate diagnosis of malaria is vital for the rapid recovery of the patient and this has raised investments in various diagnostic techniques. Diagnosis of malaria takes place by the utilization of a number of techniques such as rapid diagnostic tests (RDTs), molecular diagnostics, and by detecting parasites using microscopy.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1972

This research study has been compiled by conducting extensive market analysis and collecting inputs from leading industry experts. The study includes the market’s growth prospects in the forthcoming years. The study has been collated by using an objective combination of primary and secondary research. A number of market dynamics such as growth drivers, inhibitors, trends, and opportunities, with their respective effect on the growth of the market, are also presented in this research report.

The report employs the Porter’s five forces model, according to which the buyer’s bargaining power is high within this market owing to a number of suppliers making diagnostic kits. In the report, global initiatives taken for reducing the deaths caused by malaria have also been elaborated upon and the prime regions conducive for investment in the malaria diagnostics market have been evaluated on the basis of the future growth potential of the malaria diagnostic market.

Overview of the Malaria Diagnostics Market

Advanced malaria diagnostic tests have revolutionized malaria diagnosis and are highly demanded. These tests are used to detect the antigens of the malaria parasites. A number of diagnostic tests are utilized and amongst them, some are used to detect particular species of Plasmodium, while others are employed for the detection of multiple species.

The detection techniques for malaria include QBC technique, serological tests, and peripheral blood smears (PBS). A number of drugs are also utilized for the treatment of malaria, such as atovaquone-proguanil (Malarone), artemether-lumefantrine (Coartem), doxycycline (utilized in combination with quinine), chloroquine, clindamycin (utilized in combination with quinine), mefloquine (Lariam), quinine, and quinidine.

The increasing public awareness on malaria and the various technological developments are the prime factors stimulating the growth of the market for malaria diagnostics. On the other hand, the technological complications involved in current diagnostic tests may restrain the growth of the market in the coming years.

Request For Custom Research: http://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=1972

On the basis of geography, the malaria diagnostics market is segmented into Asia Pacific, North America, Europe, and Rest of the World (RoW). Amongst these, Asia Pacific and Europe lead the market owing to the increasing prevalence of malaria and the rising awareness on the disease amongst people here in these regions. The high fatality rate due to malaria, particularly in the younger generation, is predicted to drive the malaria diagnostics market within the developing economies of RoW and Asia Pacific.

Key players in the Malaria Diagnostics Market

The prominent players dominant in the malaria diagnostics market include Abbott Laboratories, Beckman Coulter/Danaher, bioMerieux, Bio-Rad Laboratories, Inc., Bio-Rad, Life Technology, Novartis Diagnostics, Ortho-Clinical Diagnostics, Siemens Healthcare, and Wako Chemicals, Inc., among others.

Epinephrine Market grows with increasing number of patient population susceptible to several allergic reactions

Epinephrine or adrenaline is a hormone secreted by adrenal glands in the blood stream. It is one of the two common hormones (the other being glucagon) that is responsible for glycogen breakdown. Secretion of epinephrine is characterized by the presence of extreme emotions such as anxiety or anger thereby resulting in elevated levels of blood pressure along with increased muscle strength and high sugar metabolism. Under strenuous conditions signals are transmitted to brain and brain in turn sends nerve impulses to the adrenal glands in the kidneys and result in the release or secretion of epinephrine. The presence of this hormone is essential for the body to maintain cardiovascular homeostasis as epinephrine can divert blood to tissues under stress. Epinephrine is used as a vasoconstrictor in shock, as a stimulant during cardiac arrest and as an antispasmodic and bronchodilator in bronchial asthma.

During cardiac arrest, there is a need for maximum amount of blood flow in the coronary artery and this is facilitated when epinephrine is injected into an intravenous solution. Epinephrine has effects on various parts of the body such as liver, skin, heart and lungs. For instance, in lungs epinephrine causes the relaxation of smooth muscles of lungs. Patients suffering from asthma have constricted lung passages that are prone to inflammation and swelling. This swelling result in coughing, wheezing, shortness of breath and due to inhalation of epinephrine in small doses causes the widening of the bronchial tubes thereby allowing the air to pass through and provides short term relief.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2466

Epinephrine injections are commonly used against life threatening allergic reactions caused by medications, insect bites and stings. Epinephrine injections are available as prefilled automatic injection device with the hormone in the liquid form. Epinephrine is a class of medications called as alpha and beta adrenergic agonists and these medications work by tightening the blood vessels and by relaxing the muscles in the airways. The direction for preparing and use of the injectors is dependent on different brands available in the market. This injection is usually administered on the thighs and effects of this medication are fast and quick but not long lasting. Epinephrine has both mild and serious side effects such as high blood pressure, severe headache, blurred vision, chest pain, uneven heartbeats, dizziness, nausea and vomiting.

The market for epinephrine auto-injector market exhibits tremendous growth potential owing to several technological advances towards development of innovative epinephrine injectors. Epinephrine auto injectors market can be analyzed on the basis of the product penetration and availability across the four major geographical regions namely North America, Europe, Asia-Pacific and RoW. Adrenaclick, EpiPen Auto-Injector, Adrenalin Chloride Solution and EpiPen Jr. Auto-Injector, epinephrine lidocaine hydrochloride are some of the brands of epinephrine autoinjectors.

Request For Custom Research: http://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=2466

Some of the major factors favoring the growth of this market are increasing number of patient population susceptible to several allergic reactions along with increased focus of the market players towards development of chlorofluorocarbon (CFC) free epinephrine auto-injectors. This is majorly due to the ban on the use of CFC as a propellant inhaler by the U.S. Government.

In addition, continuous product modifications, increased need and demand of automatic injection devices further propel the growth and development of epinephrine auto injectors market. On the contrary, the side effects caused by epinephrine medications pose a challenge to the growth of the market. Owing to the potential side effects (dizziness, shortness of breath and severe headache) of epinephrine therapy, doctors recommend or prescribe other alternative pharmacotherapy and immunotherapy against allergic reactions. The key market players operating in this market are Abbott Laboratories, Lincoln Medical, Ltd., Mylan, Inc., Sanofi SA, Amedra Pharmaceuticals LLC and ALK Abello A/S.

Pediatric Interventional Cardiology Market Dynamics and Opportunities Report by Transparency Market Research

Pediatric Interventional Cardiology Market: Overview

Interventional cardiology incorporates catheter based treatments for cardiac disorders and is performed by certified interventional cardiologists. Majority of the interventional cardiology procedures are considered to be minimally invasive as these do not involve the use of multiple instruments to enter the body or large incisions (open surgeries). These procedures involve the use of catheters inserted into femoral artery in the upper leg. Real time x-ray is used to guide the catheter towards heart or vascular area. There are several advantages of interventional cardiological procedures such as low risk of infection, short postoperative recovery times and avoidance of large scars.

Pediatric Interventional Cardiology Market: Trends and Opportunities

Cardiac catheterization, percutaneous valve repair, balloon valvuloplasty, embolic protection, use of stents, and atherectomy are some of the types of the interventional cardiology procedures. Disorders such as coronary artery disease, heart valve disorder and peripheral artery disorders are some of the conditions treated with the help of interventional cardiology procedures. Interventional treatment plans are recommended on a patient-by-patient basis and there are certain risks associated with interventional procedures. For instance, during angioplasty a patient may have a heart attack, coronary arteries can be damaged during the procedure and these can also lead to kidney damage and brain strokes. Complications of these procedures are blood clots, restenosis and bleeding.

Cardiac catheterization procedures are instrumental in providing care for the pediatrics with congenital heart defects. Initially these procedures were performed as diagnostics that helped determine hemodynamic information and identify child’s heart defects. However, advances in technology have altered the focus of cardiac catheterization procedures from diagnosis to treatment. Technological sophistication in devices such as catheters, balloons, stents and cardiac catheterization equipment and development of echocardiography to diagnose heart defects further support the use of these devices in enhancing the benefits of interventional cardiology procedures in children.

Pediatric interventional cardiology market exhibits immense growth potential majorly due to increasing pediatric patient base and huge unmet needs of the same.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12239

Pediatric Interventional Cardiology Market: Segmentation

The market for pediatric interventional cardiology can be analyzed on the basis of several heart disease valve closure devices along with transcatheter heart valves and others. Heart closure devices comprises atrial septal defect and ventricular septal defect closure devices, transcatheter valves are further categorized into transcatheter pulmonary and aortic valves. Angioplasty balloons, catheters, guidewires and catheters represent other interventional cardiology devices.

The geographical landscape of the market includes the analysis for four major geographies namely Asia-Pacific, North America, Europe and RoW. North America and Europe would account for the largest market shares, attributed to presence of technologically advanced healthcare infrastructure and increasing preference for minimally invasive procedures for correction of heart defects. However, with the increasing patient base and lucrative business opportunities in the emerging economies such as India and China would increase the growth of the market in these regions in near future.

Pediatric Interventional Cardiology Market: Drivers and Restraints

The factors influencing the growth of the market are continuous technological advances coupled with high degree of adoption of advanced technologies. In addition, increasing preference for minimally invasive procedures, increased investments in R&D by the market players towards development of novel devices and increased affordability of patients’ further fuel the growth of the market. On the other hand high cost of these procedures and presence of limited resources for effective diagnosis of heart defects might hamper the growth of the market.

Request For Custom Research: http://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=12239

Furthermore, focus on development of biodegradable interventional cardiology devices along with impressive growth and uptake of transcatheter heart valves would provide lucrative growth prospects for the established and emerging players in this market. St. Jude Medical, Abbott Vascular, Cordis Corporation, GE Healthcare, Medtronic, Inc., Boston Scientific Corporation and are some of the key players competing in this market.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Non-Hodgkins Lymphoma (NHL) Therapeutics Market rises with rising prevalence of Non-Hodgkin’s lymphomas (NHL)

Lymphoma is one of the most hazardous and life threatening type of cancer, related to lymphocytes, an important type of white blood cells. Non-Hodgkin’s lymphomas (NHL) is a distinct group of blood cancer, which includes large variety of lymphomas, excluding Hodgkin’s lymphomas. Non-Hodgkin’s lymphoma (NHL) varies in their severity, from mild to fatal. According to a new classification of lymphomas published by WHO in 2008, the lymphomas are segmented into four different groups, instead of segregating as Hodgkin’s and Non-Hodgkin’s lymphomas. The list comprises of around 80 various types of lymphomas.

The major causes of Non-Hodgkin’s lymphomas (NHL) include chemical interaction, such as, interaction with diphenylhydantoin, polychlorinated biphenyls and other toxic compounds, autoimmune disorders, such as, rheumatoid arthritis, celiac sprue, Sjogren’s syndrome and others, medication and radiation therapy, infections, such as, H. pylori infection, HIV infection, hepatitis C viral infection, human T-cell leukemia virus, Epstein-Barr virus and others, genetic disorders such as ataxia telangiectasis syndrome, Klienfelter’s syndrome and others. Major symptoms of the disease includes night sweats, itchy skin, frequent high fever, breath shortness, loss of appetite and weight and painless sweating of lymph nodes present on various locations in the body.

The market of Non-Hodgkin’s lymphomas (NHL) is segmented on the basis of phase of the disease (severity), such as, phase I, II, III, and IV. Further, the market is segmented on the basis of types of Non-Hodgkin’s lymphomas (NHL), such as, AIDS-related lymphomas, Mantel Cell lymphoma, cutaneous T-cell lymphoma, blastic NK-cell lymphoma, T-cell leukemia, Burkitt’s lymphoma, follicular lymphoma, Waldenstrom’s Macroglobulinemia and many others. Furthermore, the market is segmented on the basis of therapeutic agents, such as, chemotherapy, stem cell therapy, radiations, novel targeted target therapy and other. A large number of therapeutic agents are used to treat Non-Hodgkin’s lymphomas (NHL), such as methotrexate, bortezomib, cyclophosphamide, bleomycin, chlorambucil, liposomal cytarabine, nelarabine, doxorubicin hydrochloride and many others.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2668

Moreover, the market is segmented on the basis of geography, such as, North America, Europe, Asia-Pacific and Rest of the World (RoW). At present, North America and Europe are the most prominent markets, owing to extensive research practices. However, Asia-Pacific and some countries in RoW region are expected to show lucrative growth in the upcoming period, owing to enhanced awareness about cancer and growing research practices.

The market of Non-Hodgkin’s lymphomas (NHL) is driven by many promoting forces, such as, rising prevalence of Non-Hodgkin’s lymphomas (NHL) and other types of cancer, extensive R&D practices, rising concern of the population towards effects of Non-Hodgkin’s lymphomas (NHL) and rise in medical and healthcare expenditure and infrastructure. Rising prevalence of Non-Hodgkin’s lymphomas (NHL) is one of the most important market drivers. According to American Cancer Society’s recent estimations, around 71,000 new patients are diagnosed with Non-Hodgkin’s lymphomas (NHL) in 2014, and the number of deaths is expected to be around 19,000 in 2014.

Request For Custom Research: http://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=2668

Furthermore, extensive R&D practices is another important market growth factor of this market. As of now, large number of pharmaceutical companies engaged in R&D practices in order to develop innovative formulations. For instance, Rituximab SC (Roche, Inc.) is under phase III studies. On the contrary, high cost of R&D and treatment and chronic side effects are the biggest hurdles in the market growth.

Some of the key players operating in Non-Hodgkin’s Lymphoma (NHL) Therapeutics market and engaged in the development of new formulations for Non-Hodgkin’s lymphomas (NHL) include F. Hoffmann LA Roche, Inc., Amgen, Inc. ,Eli Lilly and Company, Novartis International AG, Bayer AG, Pharmacyclics, Inc., Nordic Nanovector A/S, AbbVie, Inc. and many others.

Allergic Rhinitis Market: Trends, Opportunities and Forecasts 2019

This market research report on the global allergic rhinitis market provides a comprehensive overview of the structure and the dynamics of this market. Thus, the report throws light on the factors governing the market trends in the global allergic rhinitis market. This market research report discusses the demand drivers and the various challenges facing the industry. Historical and contemporary data as included in the research study provide a strong foundation for comparative analysis and also provide a clear understanding of the progress made so far in the global allergic rhinitis market. The data, facts, and statistical figures presented in this research report form the basis for market forecasts.

This report explains the dynamics of the polyester yarn market by offering vital details on aspects such as the challenges, growth drivers, ongoing technological developments, Porter’s five forces analysis, and potential opportunities for growth.

Read Full Report: http://www.transparencymarketresearch.com/allergic-rhinitis-market.html

The market research report describes and analyzes the diverse aspects of the individual market players in the global allergic rhinitis market, such as their respective business strategies, competitive advantage, an overview of their product/service catalog, SWOT analysis, growth prospects, prevailing trends, and market restraints.

This research study also enumerates and discusses the various factors essential for the existing market players and new market entrants to thrive and prosper in the global allergic rhinitis market.

Overview of the global allergic rhinitis market

The global allergic rhinitis market is primarily driven by the increasing incidence of allergic rhinitis, rising demand for new treatments, greater respiratory anomalies, and high usage of tobacco. Allergic rhinitis refers to a chronic inflammatory disease affecting the nasal cavity, which leads to myriad respiratory disorders. This disease affects almost every age group. Nasal itching, sore throat, runny or blocked nose, and sneezing are some of the characteristic symptoms of allergic rhinitis. Allergic rhinitis is of three types, namely seasonal, perennial, and both. This disease mostly goes unnoticed because of negligence towards seemingly minor health concerns, and because its symptoms are often confused with those of the more benign common cold.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2126

The global allergic rhinitis market is segmented on the basis of the type of treatment, which include steroids, antihistamines, others, and other alternative methods of treatment.

Geographically, the global allergic rhinitis market is dominated by North America, since the U.S. has the highest incidence of this disease. The second largest market in the global allergic rhinitis market is Europe. As per industry estimates, the Asia Pacific allergic rhinitis market is currently witnessing robust growth owing to greater awareness about this disease and its treatment, and also rising incidence of allergic rhinitis. After the U.S., Japan has the highest incidence of allergic rhinitis.

Companies mentioned in the report

The various companies operating in the global allergic rhinitis market as mentioned in the report include Stallergenes S.A., Revance Therapeutics, Shionogi & Co., Ltd., Alcon, Inc., Dainippon Sumitomo Pharma Co., Ltd., Novartis AG, Array BioPharma, Inc., Genentech, Inc., Nektar Therapeutics, GlaxoSmithKline plc, and Hisamitsu Pharmaceutical Co., Inc.

Transdermal Skin Patches Market - Latest Trends & Insights 2019

Transdermal patches are pharmaceutical preparations that contain active substances. These patches apply the diffusion mechanism and are effectively used for hormonal and cardiac disorders. Transdermal skin patches are a new trend in the global skincare market. Skin gels and patches are among the modern methods used for treating many ailments. As per new research from Transparency Market Research, the global transdermal skin patches market is expected to exhibit rapid growth during the period from 2013 to 2019.

The report, titled ‘Transdermal Skin Patches Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019,’ states that the market will benefit from the rising use of transdermal skin patches as a supplement to traditional care methods. The rising number of skin diseases is also expected to propel the demand for transdermal skin patches. Transdermal skin patches deliver treatment in a non-invasive way and offer many benefits. Patches deliver medicines to the body gradually yet constantly. Skin patches are painless and bypass the acidic environment present inside the digestive system.

The first skin treatment patch, approved by the U.S. Food and Drug Administration in 1979, was used for curing motion sickness. Since then, there have been many patches introduced in the global market to treat various diseases including Parkinson’s disease and Alzheimer’s. With advancements in the medical devices sector, leading players have introduced many transdermal skin patches to cure skin issues.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2245

Transdermal skin patches comprise an inner covering and an outer covering. The inner covering contains active drugs that are delivered to cure the affected area. Transdermal gels are commonly used for treating various skin diseases as they are effective and offer quick relief. Dermal patches replace traditional oral medications in many gastric conditions including vomiting and diarrhea. Dermal patches minimize the inconvenience caused by parenteral therapies.

For a detailed analysis, the report’s authors have regionally divided the global transdermal skin patches market into Asia Pacific, Europe, North America, and Rest of the World. Presently, companies such as Mylan Pharmaceuticals Inc., Teva, Accrux Ltd., 3M Pharmaceuticals, and Access Pharmaceuticals are playing a dominant role in the global transdermal skin patches market.

Considering the growing limitations of traditional care methods to treat specific skin problems, leading players are concentrating on introducing new dermal skin patches in the global market. Analysts predict that mergers and partnerships between new entrants and leading manufacturers will create new growth opportunities in the global transdermal skin patches market.

Laboratory Filtration Equipment Market - Technological breakthroughs, Value chain and stakeholder analysis by 2020

Filtration is a necessary process step in almost all kind of laboratories related to environmental, chemistry, and life sciences applications. It is the most common technique used either to purify or concentrate samples in the laboratory. The basic equipment used for filtration process has evolved over the years and market is witnessing modern, sophisticated filtration methods capable of ultra-purifying the sample which could not have been possible with conventional methods. Laboratory filtration equipment helps an analyst in sample clarification before analysis, mobile phase filtration, sample sterilization, membrane-based microbiology, particle sampling before analysis, etc. The global market for laboratory filtration equipment is therefore driven by increase in research & development activities in the field of medicine and healthcare. The demand for these products is also increasing due to quest of producing pure and safer products with minimal risk of contamination.

The global laboratory filtration equipment market can be segmented on the basis of products, end-users and geography. On the basis of products, the market can be categorized into three major segments namely, microfiltration products, ultrafiltration products, and reverse osmosis products. The market can also be segmented on the basis of end-user of these products into segments such as academic, industrial, research, and government. On the basis of geography, the global laboratory filtration equipment market is segmented into six regions. The geographical markets include North America, Europe, Asia-Pacific, Middle East, Latin America and Africa. Historically, North America and Europe have been the leading markets in the global laboratory equipment market due to existing industrial base and high research activity in these geographies. However, in the near future countries in Asia-Pacific such as China, India and with large, developing industrial base are expected to witness highest growth in the market. The major demand in this region will stem from pharmaceutical and biotechnology companies which will spur the growth of global laboratory filtration equipment market.

Increasing health and environmental concerns have augmented the need of stringent legislations and regulation pertaining to permissible level of contaminants right from food products to industrial discharges. These regulations are highly benefitting the filtration equipment manufacturers as the demand for these products is rising consequently. The high competition among players in several industries has led to steady increase in delivery of quality products by filtering more often at micro and nano level and the demand for quality delivered is directly related to the uptake of novel filtration techniques. As the uptake of these techniques is expected to rise in near future, the market for filtration equipment is estimated to be more promising than ever. The other major driver for the growth of global laboratory filtration equipment market is the fastest growing biotechnology and pharmaceutical industry. Filtration equipment is used in both these industries for research & development, manufacturing as well as testing of products. The growth in global filtration equipment market is in line with corresponding growth in these industries.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2644

Some of the companies in the global laboratory filtration equipment market include Cantel Medical Corporation, Cuno, Dow Water & Process Solutions, FilmTec Corporation, GE Healthcare, GEA Filtration, Hydranautics, Inc., Koch Membrane Systems, Inc., Man Cor Purification, Inc., Millipore Corporation, Minntech Corporation, Pall Corporation, MACHEREY-NAGEL GmbH & Co. KG, Porex Corporation, Sartorius Stedim Biotech SA, Orbital Biosciences LLC, and Whatman plc.